FDA OKs sale of 'biosimilar' knockoff of Amgen drug

Los Angeles Times | March 6, 2015 | 8:01 AM

The Food and Drug Administration has approved the first copycat version of a biologic drug in the United States, official announced today.

The decision will allow Swiss company Novartis to sell a "biosimilar" version of Amgen Inc.’s chemotherapy recovery drug Neupogen.
Sandoz intends to market it under the brand name Zarxio.
Read more